BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 2298369)

  • 1. Gastric acid hypersecretion in refractory gastroesophageal reflux disease.
    Collen MJ; Lewis JH; Benjamin SB
    Gastroenterology; 1990 Mar; 98(3):654-61. PubMed ID: 2298369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of omeprazole and ranitidine in treatment of refractory gastroesophageal reflux disease in patients with gastric acid hypersecretion.
    Collen MJ; Strong RM
    Dig Dis Sci; 1992 Jun; 37(6):897-903. PubMed ID: 1587194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basal acid output and gastric acid hypersecretion in gastroesophageal reflux disease. Correlation with ranitidine therapy.
    Collen MJ; Johnson DA; Sheridan MJ
    Dig Dis Sci; 1994 Feb; 39(2):410-7. PubMed ID: 8313826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between basal acid output and daily ranitidine dose required for therapy in Barrett's esophagus.
    Collen MJ; Johnson DA
    Dig Dis Sci; 1992 Apr; 37(4):570-6. PubMed ID: 1551347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastroesophageal reflux disease in the elderly: more severe disease that requires aggressive therapy.
    Collen MJ; Abdulian JD; Chen YK
    Am J Gastroenterol; 1995 Jul; 90(7):1053-7. PubMed ID: 7611195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of omeprazole and high doses of ranitidine on gastric acidity and gastroesophageal reflux in patients with moderate-severe esophagitis.
    Fiorucci S; Santucci L; Morelli A
    Am J Gastroenterol; 1990 Nov; 85(11):1458-62. PubMed ID: 2239873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastric secretion and reflux pattern in reflux oesophagitis before and during ranitidine treatment.
    Johansson KE; Tibbling L
    Scand J Gastroenterol; 1986 May; 21(4):487-92. PubMed ID: 3523741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idiopathic gastric acid hypersecretion: treatment implications for refractory acid/peptic disorders.
    Lewis JH
    Aliment Pharmacol Ther; 1991; 5 Suppl 1():15-24. PubMed ID: 1888834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective study of gastric acid analysis and esophageal acid exposure in patients with gastroesophageal reflux refractory to medical therapy.
    Ahlawat SK; Mohi-Ud-Din R; Williams DC; Maher KA; Benjamin SB
    Dig Dis Sci; 2005 Nov; 50(11):2019-24. PubMed ID: 16240209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastric and esophageal acidity during continuous treatment with H2-antagonists in uncomplicated esophagitis.
    Fiorucci S; Santucci L; Perrone E; Abbritti F; Morelli A
    Scand J Gastroenterol; 1989 Aug; 24(6):671-7. PubMed ID: 2573143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of Helicobacter pylori infection in 190 control subjects and in 236 patients with gastroesophageal reflux, erosive esophagitis or Barrett's esophagus.
    Csendes A; Smok G; Cerda G; Burdiles P; Mazza D; Csendes P
    Dis Esophagus; 1997 Jan; 10(1):38-42. PubMed ID: 9079272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new physiologic approach for the surgical treatment of patients with Barrett's esophagus: technical considerations and results in 65 patients.
    Csendes A; Braghetto I; Burdiles P; Díaz JC; Maluenda F; Korn O
    Ann Surg; 1997 Aug; 226(2):123-33. PubMed ID: 9296504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral ranitidine and duration of gastric pH >4.0 in infants with persisting reflux symptoms.
    Salvatore S; Hauser B; Salvatoni A; Vandenplas Y
    Acta Paediatr; 2006 Feb; 95(2):176-81. PubMed ID: 16449023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Esophageal manometry and ambulatory 24-hour pH monitoring in patients with short and long segment Barrett's esophagus.
    Loughney T; Maydonovitch CL; Wong RK
    Am J Gastroenterol; 1998 Jun; 93(6):916-9. PubMed ID: 9647018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. pH, healing rate, and symptom relief in patients with GERD.
    Huang JQ; Hunt RH
    Yale J Biol Med; 1999; 72(2-3):181-94. PubMed ID: 10780580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
    Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
    Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The time and pH at the moment of disappearance of pyrosis induced by of esophagus acid perfusion is an indicator of hyperalgesia].
    López Gastón AR
    Acta Gastroenterol Latinoam; 2000; 30(1):15-25. PubMed ID: 10855351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is Barrett's esophagus characterized by more pronounced acid reflux than severe esophagitis?
    Coenraad M; Masclee AA; Straathof JW; Ganesh S; Griffioen G; Lamers CB
    Am J Gastroenterol; 1998 Jul; 93(7):1068-72. PubMed ID: 9672332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure.
    Ours TM; Fackler WK; Richter JE; Vaezi MF
    Am J Gastroenterol; 2003 Mar; 98(3):545-50. PubMed ID: 12650785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of acid and alkaline reflux in patients with Barrett's esophagus. G.O.S.P.E. Operative Group for the study of Esophageal Precancer.
    D'Onofrio V; Bovero E; Iaquinto G
    Dis Esophagus; 1997 Jan; 10(1):16-22; discussion 22-3. PubMed ID: 9079268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.